1月8日 - ** 制药商旺达制药VNDA.O股价盘前下跌12.65%，至7.46美元
** 该公司称已收到美国食品及药物管理局的一封信，拒绝批准 (link) 使用其睡眠药物 Hetlioz 治疗时差反应。
** FDA 指出试验使用的是模拟时差，而不是真实的空中旅行 - VNDA
** 公司表示不同意 FDA 的决定，并计划与该机构进一步谈判
** Hetlioz 已被批准用于治疗两种罕见的睡眠障碍
** 截至上次收盘，股价在过去一年中下跌了 ~3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.